These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23318440)

  • 1. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
    Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
    Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].
    Li ZW; Yang ZL; Feng HL; Bian XC; Liu YY; Liu YQ
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):330-5. PubMed ID: 24004591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
    Wallin JJ; Guan J; Prior WW; Lee LB; Berry L; Belmont LD; Koeppen H; Belvin M; Friedman LS; Sampath D
    Clin Cancer Res; 2012 Jul; 18(14):3901-11. PubMed ID: 22586300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
    Hoeflich KP; Merchant M; Orr C; Chan J; Den Otter D; Berry L; Kasman I; Koeppen H; Rice K; Yang NY; Engst S; Johnston S; Friedman LS; Belvin M
    Cancer Res; 2012 Jan; 72(1):210-9. PubMed ID: 22084396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
    McMillin DW; Ooi M; Delmore J; Negri J; Hayden P; Mitsiades N; Jakubikova J; Maira SM; Garcia-Echeverria C; Schlossman R; Munshi NC; Richardson PG; Anderson KC; Mitsiades CS
    Cancer Res; 2009 Jul; 69(14):5835-42. PubMed ID: 19584292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin displays anti-myeloma activity and synergistic effect with dexamethasone in in vitro and in vivo xenograft models.
    Zi FM; He JS; Li Y; Wu C; Yang L; Yang Y; Wang LJ; He DH; Zhao Y; Wu WJ; Zheng GF; Han XY; Huang H; Yi Q; Cai Z
    Cancer Lett; 2015 Jan; 356(2 Pt B):443-53. PubMed ID: 25305450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Knockdown of DEPTOR inhibits cell proliferation and increases chemosensitivity to melphalan in human multiple myeloma RPMI-8226 cells via inhibiting PI3K/AKT activity.
    Zhang HR; Chen JM; Zeng ZY; Que WZ
    J Int Med Res; 2013 Jun; 41(3):584-95. PubMed ID: 23613505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
    Zheng J; Wang H; Yao J; Zou X
    Pharmazie; 2014 Jan; 69(1):38-42. PubMed ID: 24601221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
    Zheng J; Zou X; Yao J
    Chemotherapy; 2012; 58(4):273-81. PubMed ID: 23006739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
    O'Brien C; Wallin JJ; Sampath D; GuhaThakurta D; Savage H; Punnoose EA; Guan J; Berry L; Prior WW; Amler LC; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2010 Jul; 16(14):3670-83. PubMed ID: 20453058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
    Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
    Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PK-PD modeling of combination efficacy effect from administration of the MEK inhibitor GDC-0973 and PI3K inhibitor GDC-0941 in A2058 xenografts.
    Choo EF; Ng CM; Berry L; Belvin M; Lewin-Koh N; Merchant M; Salphati L
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):133-43. PubMed ID: 23053270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
    Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
    Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
    Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting survival and cell trafficking in multiple myeloma and Waldenstrom macroglobulinemia using pan-class I PI3K inhibitor, buparlisib.
    Sahin I; Azab F; Mishima Y; Moschetta M; Tsang B; Glavey SV; Manier S; Zhang Y; Sacco A; Roccaro AM; Azab AK; Ghobrial IM
    Am J Hematol; 2014 Nov; 89(11):1030-6. PubMed ID: 25060991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
    Ehrhardt M; Craveiro RB; Holst MI; Pietsch T; Dilloo D
    Oncotarget; 2015 Jan; 6(2):802-13. PubMed ID: 25596739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.
    Sanchez E; Li M; Li J; Wang C; Chen H; Jones-Bolin S; Hunter K; Ruggeri B; Berenson JR
    Leuk Res; 2012 Nov; 36(11):1422-7. PubMed ID: 22906694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
    Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
    Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma.
    Wang X; Sinn AL; Pollok K; Sandusky G; Zhang S; Chen L; Liang J; Crean CD; Suvannasankha A; Abonour R; Sidor C; Bray MR; Farag SS
    Br J Haematol; 2010 Aug; 150(3):313-25. PubMed ID: 20560971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription.
    Manohar SM; Rathos MJ; Sonawane V; Rao SV; Joshi KS
    Leuk Res; 2011 Jun; 35(6):821-30. PubMed ID: 21216463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.